16 September 2026 editorial review · Trial
STRIVE: Omnipod 5 SmartAdjust 2.0 versus Omnipod 5: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: M–S
Outcome: Removed roadmap links and false universal claim about current mealautomation; sponsorconference comparison remains clearly provisional, not period3 evidence.
Registry: NCT06865989. Endpoint reviewed: Percent of time in range <54 mg/dL (non-inferiority margin of 0.75%) (End of Period 2 (Day 56) compared to Baseline); Percent of time in range <70 mg/dL (non-inferiority margin of 3.0%) (End of Period 2 (Day 56) compared to Baseline); Percent of time in range 70-180 mg/dL (non-inferiority margin of 3.0%) (End of Period 2 (Day 56) compared to Baseline); Mean Glucose (non-inferiority margin of 8 mg/dL) (End of Period 2 (Day 56) compared to Baseline). Eligibility reviewed: Age 2 Years to 70 Years; diagnosis/stage, prior therapy and key biomarker criteria compared with site summary. Full exclusions remain in the registry. Literature access limit: No usable primary abstract was independently recovered for this record in this pass. Current registry protocol was the main source; detailed sponsor or conference data remain dependent on the cited source and were not fully reverified.